Format

Send to

Choose Destination
Rheumatol Int. 2018 Apr;38(4):649-656. doi: 10.1007/s00296-017-3925-9. Epub 2018 Jan 4.

Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.

Author information

1
Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Republic of Korea.
2
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
3
Department of Information Statistics, Andong National University, Andong-si, Republic of Korea.
4
Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Republic of Korea. scbae@hanyang.ac.kr.
5
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. scbae@hanyang.ac.kr.

Abstract

The objectives of this study are to identify the prevalence and incidence of rheumatoid arthritis (RA) and to investigate the patterns of medical care and drug utilization by RA patients in Korea. Korean National Health Insurance claims data were used for analysis. RA patients were defined as those having an RA code from 2009 to 2012 and using disease-modifying anti-rheumatic drugs (DMARDs) within 1 year after the code. RA patients identified in 2010 with a disease-free period for 12 months before the index date, and those who received continuous treatment in 2011-2013 were defined as incident cases. Patterns of medical care and drug utilization were compared among subgroups. The prevalence of RA increased yearly from 0.28% in 2009 to 0.32% in 2012. The incidence of RA in 2010 was 28.5 per 100,000 person-years. The use of biologic DMARDs (bDMARDs) increased from 2.31% in 2009 to 4.05% in 2012. Hydroxychloroquine (57.53-62.45%) was the most commonly used the conventional DMARDs, followed by methotrexate (49.99-51.87%). The use of bDMARDs (1.39 vs. 2.43%) was less frequent in EORA patients than YORA patients. Hydroxychloroquine (74.96 vs. 72.11%) was more frequently used, but methotrexate (55.24 vs. 59.25%) and sulfasalazine (27.96 vs. 32.72%) were used less frequently in EORA patients than in YORA patients. The prevalence of RA has increased in Korea. EORA patients used fewer bDMARDs, methotrexate, and sulfasalazine but more hydroxychloroquine than YORA patients.

KEYWORDS:

Drug utilization; Incidence; Medical care; Prevalence; Rheumatoid arthritis

PMID:
29302803
DOI:
10.1007/s00296-017-3925-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center